Silva Pharmaceuticals Limited

DSE:SILVAPHL Stock Report

Market Cap: ৳2.0b

Silva Pharmaceuticals Valuation

Is SILVAPHL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SILVAPHL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SILVAPHL (BDT14.8) is trading above our estimate of fair value (BDT0.95)

Significantly Below Fair Value: SILVAPHL is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SILVAPHL?

Other financial metrics that can be useful for relative valuation.

SILVAPHL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA58.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SILVAPHL's PS Ratio compare to its peers?

The above table shows the PS ratio for SILVAPHL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.3x
CENTRALPHL Central Pharmaceuticals
21.9xn/a৳2.4b
SILCOPHL Silco Pharmaceuticals
5.3xn/a৳2.2b
ADVENT Advent Pharma
4.4xn/a৳2.5b
AMBEEPHA Ambee Pharmaceuticals
9.6xn/a৳2.0b
SILVAPHL Silva Pharmaceuticals
3.3xn/a৳2.0b

Price-To-Sales vs Peers: SILVAPHL is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (10.3x).


Price to Earnings Ratio vs Industry

How does SILVAPHL's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SILVAPHL is expensive based on its Price-To-Sales Ratio (3.3x) compared to the Asian Pharmaceuticals industry average (2.4x).


Price to Sales Ratio vs Fair Ratio

What is SILVAPHL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SILVAPHL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SILVAPHL's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.